Berlin - Delayed Quote ? EUR Inventiva SA (6IV.BE) Follow Compare 2.5750 +0.0750 (+2.99%) As of 4:38 PM GMT+2. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting? 2024 Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in combination GlobeNewswire ? 2 hours ago IVA IVEVF Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair. BioPharma Dive ? 6 days ago PFE AKESF JAZZ Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the “AMF”) has approved a prospectus under no. 24- GlobeNewswire ? 6 days ago IVA IVEVF Inventiva secures up to $380m for MASH treatment lanifibranor Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset. Pharmaceutical Technology ? 7 days ago IVA.PA Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? Inventiva SA (NASDAQ:IVA) stock traded higher on Monday, with a strong session volume of 8.55 million compared to an average volume of 9.91k, according to data from Benzinga Pro. The company announced it has secured financing of immediately 94.1 million euros ($99.36 million) and up to 348 million euros ($379.55 million) to fund the completion of the Phase 3 NATiV3 MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor. The Transaction wa Benzinga ? 7 days ago IVA.PA Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the filing, for the six-month period GlobeNewswire ? 7 days ago IVA IVEVF Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva’s Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomi GlobeNewswire ? 7 days ago IVA IVEVF Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Zacks ? 20 days ago IVA.PA Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive evolution of key GlobeNewswire ? 25 days ago IVA IVEVF Inventiva Reports Preliminary 2024 First-Half Financial Information1 Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012 million of short-term deposits and €9.03 million of long-term deposits as of December 31, 2023.On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng) for an amount of approximately €20.1 million.No Revenues recorded in H1 2024, compared to €1.9 million for the same perio GlobeNewswire ? 2 months ago IVA IVEVF Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrhosis due to MASH/NASH. Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on t GlobeNewswire ? 2 months ago IVA IVEVF Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of it GlobeNewswire ? 3 months ago IVA IVEVF Inventiva announces a €20.1 million issuance of royalty certificates Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term.Cash runway extended through September 2024 and evaluation of strategic and financing options pursued1. Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva GlobeNewswire ? 3 months ago IVA IVEVF Inventiva reports updates from MASH/NASH treatment study As of 5 July, the trial randomised 1,027 patients, with 784 in the main cohort, reaching 82% of the targeted enrolment. Clinical Trials Arena ? 3 months ago IVA.PA Inventiva Looking to Raise Additional Funds to Extend Cash Runway Inventiva Looking to Raise Additional Funds to Extend Cash Runway PREMIUM MT Newswires ? 3 months ago IVA.PA Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.Analysis of the baseline characteristics of all patients randomized in the main cohort of NATiV3 show a patient profile similar to patients randomized in the NATIVE Phase IIb clinical trial.A blinded analysis of all randomized patients suggests weight gain plateaus and stabilizes between week 24 and 36. First visi GlobeNewswire ? 3 months ago IVA IVEVF Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program approved by the Ordinary General Meeting of 20 June 2024, it being specified that the Company does not to date intend to pursue any objective other than to animate the market under a liquidity agreement which has been in place since the listing on Euron GlobeNewswire ? 3 months ago IVA IVEVF Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholder GlobeNewswire ? 3 months ago IVA IVEVF Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Zacks ? 4 months ago IVA.PA Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024 Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights,gross (1) Total voting rights,net (2) May 13, 2024 52 477 188 65 493 081 65 381 630 (1)The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on t GlobeNewswire ? 4 months ago IVA IVEVF Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is CAC 40 Return 6IV.BE CAC 40 YTD -37.73% +0.07% 1-Year -22.21% +10.74% 3-Year -78.68% +12.57%
